Guy W. Neff
Covenant Research and Clinics (United States) · 239 works · 12,392 citations · h-index 48
Top works
- Rifaximin Treatment in Hepatic Encephalopathy
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
- Survival of Human Immunodeficiency Virus–Infected Liver Transplant Recipients
- A Retrospective Review of Liver Transplant Patients Treated with Sirolimus from a Single Center: An Analysis of Sirolimus-Related Complications
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
- The current economic burden of cirrhosis.
- Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- Nonalcoholic Fatty Liver Disease Epidemic and Its Implications for Liver Transplantation
- Treatment of Established Recurrent Hepatitis C in Liver-Transplant Recipients with Pegylated Interferon-alfa-2b and Ribavirin Therapy
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- Ten years of sirolimus therapy in orthotopic liver transplant recipients
- Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy
- Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid
- Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
- Access to Liver Transplantation in the MELD Era: Role of Ethnicity and Insurance